- Home
- CODA vs QNCX Comparison
CODA vs QNCX Comparison
Compare CODA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODA
- QNCX
- Stock Information
- Founded
- CODA 1994
- QNCX 2012
- Country
- CODA United States
- QNCX United States
- Employees
- CODA N/A
- QNCX N/A
- Industry
- CODA Industrial Machinery/Components
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CODA Industrials
- QNCX Health Care
- Exchange
- CODA Nasdaq
- QNCX Nasdaq
- Market Cap
- CODA 88.8M
- QNCX 85.9M
- IPO Year
- CODA N/A
- QNCX 2019
- Fundamental
- Price
- CODA $8.08
- QNCX $1.65
- Analyst Decision
- CODA Strong Buy
- QNCX Strong Buy
- Analyst Count
- CODA 1
- QNCX 6
- Target Price
- CODA $11.00
- QNCX $8.00
- AVG Volume (30 Days)
- CODA 80.8K
- QNCX 118.4K
- Earning Date
- CODA 09-15-2025
- QNCX 11-12-2025
- Dividend Yield
- CODA N/A
- QNCX N/A
- EPS Growth
- CODA 15.09
- QNCX N/A
- EPS
- CODA 0.30
- QNCX N/A
- Revenue
- CODA $24,347,217.00
- QNCX N/A
- Revenue This Year
- CODA $30.82
- QNCX N/A
- Revenue Next Year
- CODA $20.84
- QNCX N/A
- P/E Ratio
- CODA $26.33
- QNCX N/A
- Revenue Growth
- CODA 29.34
- QNCX N/A
- 52 Week Low
- CODA $5.76
- QNCX $0.69
- 52 Week High
- CODA $9.89
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CODA 52.95
- QNCX 53.76
- Support Level
- CODA $7.85
- QNCX $1.56
- Resistance Level
- CODA $8.80
- QNCX $1.65
- Average True Range (ATR)
- CODA 0.38
- QNCX 0.07
- MACD
- CODA 0.01
- QNCX -0.08
- Stochastic Oscillator
- CODA 39.50
- QNCX 98.80
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.